Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Now watching

Next video starts in : 7 Play

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People
Replay video
Up next

What to Watch Friday: Consumer Income, Spending, & Sentiment

Unlock your personal NFL Now stream by signing in to NFL.com

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

by TheStreet 1:02 mins

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

by TheStreet 1:02 mins

New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York.

TheStreet

Finance

  1. 1:01

    The Biebs is back: Justin Bieber by the numbers

  2. 1:04

    Yahoo Finance cocktail of the week: The wild ride

  3. 14:54

    Markets calm down, Sprint vs. AT&T and 'sky high' wifi prices

  4. 4:23

    China fears linger as focus on Fed sharpens

  5. 3:34

    China's Wanda buys Ironman Triathlon owner for $650 mln

  6. 2:31

    Sky high wifi prices

Personal Finance

  1. 3:44

    A local man’s view on the real recovery of post-Katrina New Orleans

  2. A local man’s view on the real recovery of post-Katrina New Orleans

  3. 1:40

    How Much Money Do You Need to Be Rich? Kids' Answers Will Inspire You.

  4. 1:34

    Young people and startups are fueling New Orleans’ recovery after Hurricane Katrina

  5. 1:52

    Here's how smart investors will react to today's market drama

  6. 2:33

    In post-Katrina New Orleans, black men lift each other up

Investing

  1. 1:39

    Icahn buys into FCX, big changes at BIG, ULTA looking pretty

  2. 1:52

    Three tests face a market shaken by volatility storm

  3. 1:31

    3 tips for managing money in a volatile market

  4. 3:52

    Analyst trolls Chanos, says he's lying about Elon Musk's SolarCIty

  5. 3:47

    Unhinged market tests Wall Street rules of thumb

  6. 5:03

    No fundamental reason for oil's 'meltdown': energy analyst

Market Movers